USPTO serial 86837302
RENVIVO
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- DENNIS, SETH OWEN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with RENVIVO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Pollie Gautsch
POLLIE GAUTSCH G&A LEGAL, APC2033 SAN ELIJO #201CARDIFF, CA 92007UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents, namely, a solution used for scientific and medical research purposes for handling of mammalian cells which keeps cells disaggregated, round and stopped in a stabile state while stabilizing membranes, membrane markers, membrane receptors and cluster differentiation (CD) markers; eukaryotic cell culture reagents, namely, a solution that contains enzymes for detaching and disassociating attached mammalian cell culture from the growth substrates for scientific research use or medical research use; Chemical preparations for scientific and medical research use, namely, sterile solutions that keeps dissociated eukaryotic cells round and unattached for long periods of time and blocks attachment to plastic surfaces for scientific and medical research purposes; chemical preparations for scientific and medical laboratory use, namely, a chemical solution for increasing recombinant protein or monoclonal antibody production from cultures of mammalian cells, except for medical or veterinary use | ACTIVE | — |
| 005 | Organ preservation solutions for medical transplant use, namely, storage and preservation solution for machine perfusion of animal and human organs, tissues, and cells, specifically kidneys, abdominal organs and tissues, thoracic organs and tissues, and stem cells, for the purpose of transplantation; Nutrient-based solutions for medical use to store and treat cells, tissues, and organs in order to sustain life-providing systems, namely, solutions composed of complex mixtures of the nutrients required to support the normal cellular biochemistry and physiology, ex-vivo or in vitro, of living cells, tissues, and organs while preventing or slowing their death; Organ preservation solutions for medical transplant use, namely, a static, hypothermic, flushing, transport, and storage solution for animal and human organs, tissues, and cells, specifically whole hearts, heart tissue, cardiomyocytes, and stem cells, for the purpose of transplantation; Organ preservation solutions for medical transplant use, namely, storage and preservation solution for donor animal tissues and organs for the purpose of transplantation and for use in long-term mesothermic machine perfusion and ex-vivo healing and repair of tissues and organs; cell culture media for medical and veterinary use, namely, protein-free media for growing cells in biomedical and mammalian cell culture applications; Nutrient-based solutions for medical use in applications which require the support of life-providing systems in cells, tissues and organs, namely, solutions composed of complex mixtures of the nutrients required to support the normal cellular biochemistry and physiology, ex-vivo or in vitro, of living cells, tissues and organs while preventing or slowing their death; Nutritive substances for microorganism cultures for medical use, namely, a production boosting chemical solution for increasing recombinant protein or monoclonal antibody production from cultures of mammalian cells; Medical transplant solutions, namely, cornea preservation solutions used to aid in the flushing, transporting, storing, and preserving of animal corneas, eye tissues, eye cells, and stem cells for medical transplants | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Global Medical & Research Technologies, Inc.
- Other trademarks owned by Global Medical & Research Technologies, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named RENVIVO
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 20, 2017 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 20, 2017 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 16, 2016 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 21, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 21, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 1, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 16, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 6, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 6, 2016 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 6, 2016 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 6, 2016 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 6, 2016 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 18, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 18, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 8, 2016 | ALIE | ASSIGNED TO LIE | — |
| Mar 28, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 23, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 23, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 23, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 21, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 8, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 5, 2015 | NWAP | NEW APPLICATION ENTERED | — |